Xponance Inc. Buys New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Xponance Inc. bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,031 shares of the company’s stock, valued at approximately $306,000.

A number of other hedge funds have also modified their holdings of TMDX. Wasatch Advisors LP acquired a new position in shares of TransMedics Group in the first quarter valued at about $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new position in shares of TransMedics Group in the second quarter valued at about $39,862,000. First Light Asset Management LLC increased its holdings in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the period. Hood River Capital Management LLC acquired a new position in shares of TransMedics Group in the second quarter valued at about $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of TransMedics Group in the second quarter valued at about $16,086,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock worth $9,650,880 over the last quarter. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $144.82 on Wednesday. The company has a market capitalization of $4.83 billion, a P/E ratio of -425.94 and a beta of 1.99. The business’s 50 day moving average is $156.20 and its two-hundred day moving average is $133.11. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.03) earnings per share. Analysts expect that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Analyst Ratings Changes

TMDX has been the topic of a number of research reports. TD Cowen increased their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler upped their target price on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, Needham & Company LLC began coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $174.30.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.